

**Client**  
**Gurugram**  
Pathkind Diagnostics Pvt. Ltd.  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

**Processed By**  
**Pathkind Diagnostics Pvt. Ltd.**  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

<b>Name</b> : Mr. CL26F	<b>Billing Date</b> : 07/07/2023 12:31:29
<b>Age</b> : 35 Yrs	<b>Sample Collected on</b> : 10/07/2023 10:01:31
<b>Sex</b> : Male	<b>Sample Received on</b> : 10/07/2023 11:02:13
<b>P. ID No.</b> : P1000100012932	<b>Report Released on</b> : 15/07/2023 11:21:26
<b>Accession No</b> : 10002304988	<b>Barcode No.</b> : 10002304988-01
<b>Referring Doctor</b> : Self	
<b>Referred By</b> :	<b>Ref no.</b> :

**Report Status - Final**

Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**BIOCHEMISTRY**

<b>CEA, Fluid</b> <i>Sample: Fluid</i> <i>Method: CMIA</i>	2.06	Not Defined	ng/mL
--	------	-------------	-------

**CEA, Fluid**

Clinical Significance :

Carcinoembryonic antigen (CEA) level is increased in patients colorectal cancer or other malignancies including medullary thyroid carcinoma and breast, gastrointestinal tract, liver, lung, ovarian, pancreatic, and prostatic cancers. Serial monitoring of CEA should begin before therapy is started to verify post therapy decrease in concentration and to establish a baseline for evaluating possible recurrence.

\*\* End of Report\*\*



**Dr. Aarti Khanna Nagpal**  
DNB (Pathology)  
Senior Consultant

